Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone+Bupropion for Binge Eating Disorder
NCT03539900Phase 3Completed
- Sponsor
- Yale University
- Start
- Apr 2018
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of naltrexone + bupropion in binge eating disorder (BED), sponsored by Yale University. Started Apr 2018; status: completed.
02
Drugs
naltrexone + bupropion
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT03539900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03539900.